It began typically enough: the Supreme Court denied cert in Athena, Chargepoint and Trading Technologies; Brexit finally happened; the Federal Circuit refused to rehear Arthrex; and the IP community was waiting for important rulings in copyright cases like Google v. Oracle and trademark cases like Booking.com. But then came COVID. Courts and offices shut down, the USPTO went almost 100% remote, and all conferences and events were cancelled into 2021. At the same time, pharmaceuticals, vaccines – and the IP around them – became the only thing on anyone’s mind.
Patent
- Enablement
- Fee Shifting
- Litigation
- CAFC Gives Google Second Shot at PTAB in Challenge of Communications Patents
- Policy Shift Against SEP Rights Poses Risks for U.S. Innovation and Undermines Mandate of the ITC
- Mossoff-Barnett Comment on EU Commission’s Call for SEP Evidence Spotlights Misconceptions About FRAND Obligations
- LG’s Recent Infringement Fight Against TCL Could Take Some Tips from DivX’s Approach
- A Tale of Two Googles: Patent System Champion or Crux of the Problem?
Recent Posts
- CAFC Gives Google Second Shot at PTAB in Challenge of Communications Patents
- Policy Shift Against SEP Rights Poses Risks for U.S. Innovation and Undermines Mandate of the ITC
- Mossoff-Barnett Comment on EU Commission’s Call for SEP Evidence Spotlights Misconceptions About FRAND Obligations
- LG’s Recent Infringement Fight Against TCL Could Take Some Tips from DivX’s Approach
- A Tale of Two Googles: Patent System Champion or Crux of the Problem?